Takeda (TAK) insider plans Rule 144 sale of 87,023 ADSs on NYSE

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited has an affiliated holder filing a notice to sell American Depositary Shares (ADSs) under Rule 144. The planned sale covers 87,023 ADSs with an aggregate market value of $1,242,688.44, to be executed through Interactive Brokers LLC on the NYSE, with an approximate sale date of 12/05/2025. The table notes that 123,490,548 ADSs are outstanding.

The securities to be sold were acquired as compensation through vested restricted stock unit (RSU) awards from Takeda on three dates: 99,692 ADSs on 07/01/2023, 31,896 ADSs on 07/01/2022, and 17,200 ADSs on 07/01/2021. By signing the notice, the selling person represents that they are not aware of any material adverse, nonpublic information about Takeda’s current or prospective operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	87023	1242688.44	123490548	12/05/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2023	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			99692	07/01/2023	Compensation
ADSs	07/01/2022	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			31896	07/01/2022	Compensation
ADSs	07/01/2021	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			17200	07/01/2021	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does this Form 144 filing related to TAK represent?

This Form 144 indicates that a person affiliated with Takeda Pharmaceutical Company Limited (TAK) intends to sell ADSs under Rule 144, which governs sales of restricted and control securities.

How many Takeda (TAK) ADSs are planned to be sold and at what value?

The notice covers a planned sale of 87,023 American Depositary Shares (ADSs) with an aggregate market value of $1,242,688.44 as shown in the filing.

When and where are the Takeda (TAK) ADSs expected to be sold?

The approximate date of sale listed is 12/05/2025, with trades to be carried out on the NYSE through Interactive Brokers LLC.

How were the Takeda (TAK) ADSs being sold originally acquired?

The ADSs were acquired as compensation via vested restricted stock unit (RSU) awards from Takeda on three dates: 07/01/2021, 07/01/2022, and 07/01/2023, totaling 99,692, 31,896, and 17,200 ADSs respectively.

How many Takeda (TAK) ADSs are outstanding according to this filing?

The securities information table states that 123,490,548 ADSs of Takeda are outstanding.

What representation does the selling holder make in this Takeda (TAK) Form 144?

By signing, the holder represents that they do not know of any material adverse information about Takeda’s current or prospective operations that has not been publicly disclosed.

Does the Takeda (TAK) Form 144 mention a Rule 10b5-1 trading plan?

The form explains that if the person uses a written trading plan or trading instructions to satisfy Rule 10b5-1, their signature also makes the same representation as of the date the plan or instruction was adopted.